Healthcare Services

Neurogenomics Market Growth Expected to Reach $2.98 Billion by 2030 with 14.7% CAGR

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Neurogenomics Market In 2026 And What Value Is Projected For 2030?

The neurogenomics market has demonstrated rapid expansion in recent years. This market is projected to expand from $1.5 billion in 2025 to $1.72 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.7%. Factors contributing to its past expansion include improvements in genomic sequencing technologies, an increase in neuroscience research funding, the rising occurrence of neurological disorders, enhanced accessibility of bioinformatics tools, and a boost in academic research collaborations.

The neurogenomics market size is projected to experience substantial growth in the upcoming years. It is set to expand to $2.98 billion by 2030, with a compound annual growth rate (CAGR) of 14.7%. This anticipated growth during the forecast period is primarily driven by the increasing integration of genomics in clinical neurology, rising investments in precision neurology, the expansion of cloud-based genomic analytics, a growing demand for personalized neurological therapies, and an increasing focus on translational neuroscience research. Major trends predicted for the forecast period include a greater adoption of next-generation sequencing in neuroscience, the rising use of multi-omics data integration, an escalating demand for gene expression analysis in neurology, the expansion of personalized neurological research, and an enhanced focus on data-driven brain disorder studies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25845&type=smp

What Key Drivers Are Influencing The Growth Of The Neurogenomics Market?

The increasing occurrence of neurological disorders is anticipated to stimulate the expansion of the neurogenomics market. Neurological disorders are defined as medical conditions affecting the brain, spinal cord, or nerves, which can manifest as symptoms such as muscle weakness, seizures, pain, or cognitive difficulties. This growing prevalence of neurological disorders is largely attributable to lifestyle factors like poor diet, insufficient physical activity, chronic stress, and heightened exposure to environmental toxins. Neurogenomics provides a deeper understanding of the genetic foundation of brain function and its impairments, thereby enabling the identification of underlying causes, improved diagnostic methods, and more targeted treatments for neurological disorders. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, a figure projected to increase to 13.8 million by 2060. Thus, the rising incidence of neurological disorders is significantly contributing to the growth of the neurogenomics market.

What Are The Key Segments Of The Neurogenomics Market?

The neurogenomics market covered in this report is segmented –

1) By Offering: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Software And Services

2) By Application: Variant Discovery, Research Applications, Target Identification, Transcription Factor Binding Analysis, Functional Studies, Clinical Applications

3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Diagnostic Laboratories

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, Ribonucleic Acid Sequencing

2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Digital Polymerase Chain Reaction

3) By Microarray: Deoxyribonucleic Acid Microarray, Ribonucleic Acid Microarray, Protein Microarray

4) By Software And Services: Data Analysis And Interpretation Software, Genomic Data Management Tools, Custom Services, Cloud-Based Platforms And Reporting Tools

What Major Market Trends Are Driving Changes In The Neurogenomics Market?

Leading companies in the neurogenomics market are concentrating on developing sophisticated solutions, such as whole genome sequencing platforms, to enhance the diagnosis and understanding of complex neurological disorders. These whole genome sequencing platforms are instruments used to analyze an individual’s complete DNA sequence, thereby assisting in identifying genetic factors linked to neurological disorders. For instance, in April 2023, Centogene N.V., a Germany-based company involved in diagnosing and researching rare diseases, introduced CentoGenome, described as the world’s most comprehensive whole-genome sequencing (WGS) solution for diagnosing rare and neurodegenerative diseases. This platform employs PCR-free technology to facilitate high-quality, unbiased sequencing across intricate genetic regions. It improves variant detection by utilizing an advanced bioinformatics pipeline and expert interpretation, identifying nearly all disease-causing variants in a single test. Additionally, it offers integrated, lifelong diagnostic support, which includes free variant reclassification and confirmatory testing as new scientific knowledge becomes available.

Who Are The Leading Companies Operating In The Neurogenomics Market?

Major companies operating in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc, PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., BGI Genomics Co. Ltd., GenScript Biotech Corporation, Roche Diagnostics GmbH, Illumina Cambridge Ltd.

Read the full neurogenomics market report here:

https://www.thebusinessresearchcompany.com/report/neurogenomics-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Neurogenomics Market?

North America was the largest region in the neurogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurogenomics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25845&type=smp

Browse Through More Reports Similar to the Global Neurogenomics Market 2026, By The Business Research Company

Genetic Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Prenatal And Newborn Genetic Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report

Dna Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795